IL-6,IL-8,IP-10,MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus

Abstract

Objective

To determine whether the intrathecal concentrations of cytokines/chemokines are associated with, or influenced by, serum concentrations in patients with central neuropsychiatric systemic lupus erythematosus (NPSLE), and to ascertain whether the increased production of cytokines/chemokines intrathecally relative to serum levels is associated with the presence of central NPSLE.

Methods

52 SLE patients (30 with central NPSLE and 22 with non-NPSLE), for whom the CSF and serum samples were obtained at the same time, were enrolled. 27 kinds of cytokine/chemokine concentrations other than IFN-α in the cerebrospinal fluid (CSF) and serum samples were measured by Bio-Plex Pro Assays. IFN-α concentration and anti-ribosomal P protein antibody (anti-P) titres in CSF and serum samples were measured by ELISA.

Results

The mean concentrations of IL-6, IL-8, IP-10, MCP-1, G-CSF and GM-CSF were higher in the CSF than in the sera, respectively, while the mean concentrations of other 22 cytokines/chemokines, including RANTES and IFN-α, in the CSF were much lower than those in the sera, respectively. Furthermore, the concentrations of IL-6, IL-8, IP-10, MCP-1 and G-CSF in the CSF of the 30 patients with NPSLE were significantly higher than in the 22 patients with non-NPSLE (p = 6.82 × 10⁻⁵, p = 0.00037, p = 0.0028, p = 0.00065, and p = 0.0001, respectively), while the concentration of GM-CSF in the CSF of the 30 patients with NPSLE was not significantly higher than in the 22 patients with non-NPSLE. Most importantly, the largest difference occurred in CSF IL-6 concentrations. A significant positive correlation between CSF anti-P titres and serum anti-P titres in 52 patients with SLE (r = 0.6316, p = 6.44 × 10⁻⁶) was found, while no significant positive correlation was observed between CSF levels and serum levels of each cytokine/chemokine in the 52 SLE patients.

Conclusion

In central NPSLE the production of IL-6, IL-8, IP-10, MCP-1 and G-CSF might take place in the central nervous system (CNS). These increased CSF cytokines/chemokines along with anti-P might have a prerequisite role in the pathogenesis of central NPSLE.

Keywords

Central neuropsychiatric lupus erythematosus cerebrospinal fluid IL-6 IL-8 IP-10 MCP-1 G-CSF antiribosomal P protein antibodies

Get full access to this article

View all access options for this article.

References

Hanly

Liang

. Cognitive disorders in systemic lupus erythematosus: epidemiologic and clinical issues. Ann NY Acad Sci 1997; 823: 60–68.

Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014; 10: 338–47.

Gibson

Myers

. Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 1975; 35: 398–406.

Harris

Hughes

. Cerebral disease in systemic lupus erythematosus. Springer Semin Immunopathol 1985; 8: 251–266.

Trysberg

Carlsten

Tarkowski

. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000; 9: 498–503.

Svenungsson

Andersson

Brundin

. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 2001; 60: 372–379.

Iikuni

Okamoto

Yoshio

. Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus. Ann Rheum Dis 2006; 65: 253–256.

Okamoto

Iikuni

Kamitsuji

Yoshio

Minota

Kamatani

. IP-10/MCP-1 ratio in CSF is an useful diagnostic marker of neuropsychiatric lupus patients. Rheumatology 2006; 45: 232–234.

Okamoto

Katsumata

Nishimura

Kamatani

. Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus. Arthritis Rheum 2004; 50: 3731–3732.

10.

Fragoso-Loyo

Richaud-Patin

Orozco-Narváez

. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1242–1250.

11.

Gilad

Lampl

Eshel

Barak

Sarova-Pinhas

. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol 1997; 36: 190–193.

12.

Jönsen

Bengtsson

Nived

. The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles. Lupus 2003; 12: 846–850.

13.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

14.

ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599–608.

15.

Bombardier

Gladman

Urowitz

Caron

Chang

. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

16.

Yoshio

Masuyama

Ikeda

. Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol 1995; 22: 1681–1687.

17.

Yoshio

Hirata

Onda

Nara

Minota

. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 2005; 32: 34–39.

18.

Okamoto

Kobayashi

Yamanaka

. Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus. J Biomed Biotechnol 2010; 2010: 268436–268436.

19.

Hirohata

Miyamoto

. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33: 644–649.

20.

Hirohata

Hayakawa

. Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2729–2730.

21.

Hirohata

Kanai

Mitsuo

Tokano

Hashimoto

. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. a multicenter retrospective study. Clin Rheumatol 2009; 28: 1319–1323.

22.

Trysberg

Nylen

Rosengren

Tarkowski

. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48: 2881–2887.

23.

Matsushita

Tateishi

Isobe

. Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoSOne 2013; 8: e61835–e61835.

24.

Lenhoff

Rosberg

Olofsson

. Granulocyte interactions with GM-CSF and G-CSF secretion by endothelial cells and monocytes. Eur Cytokine Netw 1999; 10: 525–532.

25.

Schneider

Kruger

Steigleder

. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005; 115: 2083–2098.

26.

Pitzer

Krüger

Plaas

. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 2008; 131: 3335–3347.

27.

Yoshio

Okamoto

Hirohata

Minota

. Anti-NR2 glutamate receptor auto-IgG antibodies from patients with systemic lupus erythematosus activate endothelial cells. Arthritis Rheum 2013; 65: 457–463.

28.

Cassatella

Gasperini

Calzetti

Bertagnin

Luster

McDonald

. Regulated production of the interferon-gamma-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur J Immunol 1997; 27: 111–115.

29.

Deshmane

Kremlev

Amini

Sawaya

. Monocyte Chemoattractant Protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313–326.

30.

Yoshio

Masuyama

Kano

. Antiribosomal P0 protein antibodies react with the surface of human umbilical vein endothelial cells. J Rheumatol 1996; 23: 1311–1312.

31.

Yoshio

Okamoto

. Pathogenesis of neuropsychiatric syndromes of systemic lupus erythematosus. Open J Rheumatol Autoimmun Dis 2015; 5: 46–56.